Helmholtz-zentrum Fur Infektionsforschung Gmbh

Eberhard Karls Universitat Tubingen Medizinische F Akultat

Helmholtz-Zentrum FÜr Infektionsforschung Gmbh FÜr Das Helmholtz-Institut FÜr Pharmazeutische Forschung Saarland (Hips)

Brigitta Loretz

Michael Kormann

Claus-Michael Lehr

Lauren Mays Weddle

Emad Malaeksefat

Duy-Khiet Ho

Lauren Mays

The present invention relates to conjugates of aminoglycosides and terpenoids, in particular sesquiterpenoids. Furthermore, the present invention relates to nano-assemblies formed by the inventive conjugates and to a method for producing the conjugates and/or the nano-assemblies. The present invention also relates to the inventive conjugates and nano-assemblies for use in therapy, in particular for use in the treatment of infectious diseases. Particularly preferred embodiments of the present invention relate to farnesylated aminoglycosides and nano-assemblies thereof, in which farnesol and its derivatives do not only function as carrier for the aminoglycosides but do themselves have pharmaceutical activity upon cleavage of the conjugate, in particular quorum sensing inhibitory activity.

Aminoglycoside derivatives and nano-assemblies thereof, including those with quorum sensing inhibitory function

The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.

Permanent gene correction by means of nucleotide-modified messenger RNA

Growing community of inventors

Saarbrücken, Germany

Brigitta Loretz